Roberts Glore & Co. Inc. IL Makes New $580,000 Investment in Zimmer Biomet Holdings, Inc. $ZBH

Roberts Glore & Co. Inc. IL acquired a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the second quarter, HoldingsChannel.com reports. The fund acquired 6,742 shares of the medical equipment provider’s stock, valued at approximately $580,000.

Several other hedge funds also recently made changes to their positions in the company. DV Equities LLC bought a new stake in Zimmer Biomet during the 4th quarter valued at $25,000. Tacita Capital Inc bought a new position in shares of Zimmer Biomet during the second quarter valued at about $26,000. Ancora Advisors LLC purchased a new stake in shares of Zimmer Biomet during the second quarter worth about $29,000. Monetary Solutions Ltd bought a new stake in shares of Zimmer Biomet in the fourth quarter worth about $30,000. Finally, Gen Wealth Partners Inc bought a new position in Zimmer Biomet during the 4th quarter valued at approximately $31,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on ZBH shares. Canaccord Genuity Group boosted their target price on Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a research note on Monday, August 10th. JPMorgan Chase & Co. cut their price target on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating on the stock in a report on Wednesday, April 29th. Truist Financial upped their price objective on shares of Zimmer Biomet from $92.00 to $106.00 and gave the stock a “hold” rating in a report on Thursday, August 6th. Stifel Nicolaus lifted their target price on shares of Zimmer Biomet from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Citizens Jmp reduced their price target on shares of Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating on the stock in a research report on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus target price of $104.42.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the transaction, the insider owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This trade represents a 15.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.28% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $100.25 on Wednesday. The company’s fifty day moving average price is $93.11 and its 200-day moving average price is $91.22. The stock has a market cap of $19.12 billion, a PE ratio of 24.39, a price-to-earnings-growth ratio of 2.75 and a beta of 0.45. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a 12 month low of $79.12 and a 12 month high of $108.29.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The company had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.13 billion. During the same period last year, the business earned $2.07 EPS. Zimmer Biomet’s quarterly revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.